Key regions: Australia, Japan, United States, Germany, Europe
The demand for Anti-Coagulants in Fiji has been growing steadily over the past few years.
Customer preferences: Fijians, like many other countries, are aging and the elderly population is more prone to heart diseases and blood clots. As a result, there has been an increase in demand for Anti-Coagulants. Additionally, the rise in non-communicable diseases such as diabetes, hypertension, and obesity has also contributed to the growth of the Anti-Coagulants market in Fiji.
Trends in the market: The Anti-Coagulants market in Fiji is dominated by multinational pharmaceutical companies that have established a strong presence in the country. These companies have been investing in research and development to introduce new drugs and therapies in the market. One of the trends observed in the market is the shift towards novel oral anticoagulants (NOACs) which are more effective and have fewer side effects compared to traditional anticoagulants.
Local special circumstances: One of the unique challenges that the Anti-Coagulants market faces in Fiji is the lack of awareness among the general population about the risks associated with blood clots and the importance of preventive measures. There is a need for more education and awareness campaigns to be conducted to inform the public about the benefits of Anti-Coagulants and how they can reduce the risk of heart attacks and strokes.
Underlying macroeconomic factors: The Fijian government has been investing heavily in the healthcare sector, which has led to an increase in access to healthcare services for the population. The rise in disposable income and the growth of the middle class has also contributed to the growth of the Anti-Coagulants market in Fiji. Furthermore, the country's strategic location in the South Pacific has made it a hub for medical tourism, which has also contributed to the growth of the Anti-Coagulants market as more patients seek treatment for heart diseases and blood clots in Fiji.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
